Recent private placements and follow-on financings show that despite public company valuations being down across the board during the past two years, it still is possible to drum up investor support for biopharmaceutical success stories. Unfortunately, companies with no immediate major milestones to report – or that have had to disclose bad news – continue to be faced with tough decisions aimed at preserving cash on hand until they can raise money again.
Fortunately for Arvinas, Inc., Pharvaris B.V., Xenon Pharmaceuticals, Inc. and five of their peers, investors recently were...
